The possible benefit of LASP1 as a biomarker is not restricted to cancer, as LASP1 is one out of 12 differentially expressed proteins that show decreased expression in cultured skin fibroblasts of insulin-dependent type 1 diabetes mellitus patients with diabetic nephropathy versus diabetics without nephropathy or healthy subjects. Here, LASP1 is linked to diabetic kidney disease.